NCT04081285

Brief Summary

Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay. The objective of this study is to improve our understanding of the risk factors of LOAD by conducting an epigenome wide study within patients of LOAD contrasted against their cognitively normal siblings.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 9, 2019

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2024

Completed
Last Updated

April 29, 2025

Status Verified

April 1, 2025

Enrollment Period

5.3 years

First QC Date

July 23, 2019

Last Update Submit

April 25, 2025

Conditions

Alzheimer Disease

Outcome Measures

Primary Outcomes (3)

  • DNA methylation

    5 years

  • RNA-seq microbiome

    5 years

  • Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog)

    5 years

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Alzheimer's disease patients and normal siblings

You may qualify if:

  • Sufficient Cantonese competency for cognitive test
  • Written informed consent given
  • Have at least one gender-matched cognitively normal sibling

You may not qualify if:

  • Subjects who refuse blood taking procedure
  • Do not have a reliable family/caregiver informant (personal contact at least once a month)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Timothy Kwok

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 23, 2019

First Posted

September 9, 2019

Study Start

September 1, 2019

Primary Completion

November 30, 2024

Study Completion

November 30, 2024

Last Updated

April 29, 2025

Record last verified: 2025-04

Locations

HK(1)